Cointime

Virvio

company

About

Developer of a broadly-protective influenza therapeutic.

  • 1 - 10

Highlights

Total Funding Amount
$209K
Funding Rounds
1
Investors
1

Details

Last Funding Type
Grant
Last Funding Money Raised
$209K
Industries
Health Care,Therapeutics
Founded date
Dec 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Virvio is a pre-clinical biotherapeutic company developing a broadly-neutralizing peptide capable of both pre- and post- exposure containment of influenza. The drug candidate is being developed as a shelf-stable, single-dose, inhaled product suitable for stockpiling and global pandemic preparedness.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$209K
Virvio has raised a total of $209K in funding over 2 rounds. Their latest funding was raised on Feb 15, 2016 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 15, 2016 Grant $209K 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Virvio is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health — Grant
Cointime
เนื้อหา
บริษัท